Anavex Life Sciences Corp (AVXL)

[falconer66a]

Price Decline

I see that the NASDQ continues to slide; taking with it AVXL.

The average cost basis of my several thousand AVXLs is a bit under three bucks. Will be interesting to see how close to that the share price declines; until the positive clinical results are released sometime in the future.

From the start of my incremental acquisition of my AVXL position, about a half-decade ago, I recognized that getting a new drug, with a new MOA (mechanism of action), treating central nervous system diseases, would take time; many years. But we are getting ever closer. Top line date (TLD) results from the concluding Parkinson’s disease dementia trial is likely to initiate the AVXL share price climb, if it doesn’t start with the Alzheimer’s TLD. The Rett study data will be the third horse in the Anavex trifecta.

2023 will be Anavex’s year. I’ve waited this long, can wait longer. For both patients and stockholders, the wait will be rewarded. All depends on where one chooses to peer; at the near-term day to day share prices, or the ones a year out? Knowing the Anavex science, I confidently take the long perspective.